Morphic to Present at November Investor Conferences

11/10/23 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MORF alert in real time by email

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.

Jefferies London Healthcare Conference Fireside Chat

Date: Tuesday, November 14, 2023

Time: 5:00 PM GMT/12:00 PM ET

A live webcast of the presentation will be available on the Investor section of the Morphic website. An archived replay will be available on the company's website following the conference.

Evercore ISI HealthCONx Conference Presentation

Date: Thursday, November 30, 2023

Time: 9:10 AM ET

A live webcast of the presentation will be available on the Investor section of the Morphic website. An archived replay will be available on the company's website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts

Morphic Therapeutic

Chris Erdman

[email protected]

617.686.1718

Get the next $MORF alert in real time by email

Recent Analyst Ratings for

$MORF

Date	Price Target	Rating	Analyst
12/8/2023	$46.00	Buy	Citigroup
9/25/2023	$61.00 → $33.00	Hold	Stifel
9/25/2023		Buy → Neutral	BTIG Research
8/9/2023	$69.00 → $61.00	Buy → Hold	Stifel
9/7/2022	$44.00	Buy	Stifel
7/20/2022	$45.00	Outperform	SVB Leerink
3/31/2022	$68.00	Buy	Canaccord Genuity
2/25/2022	$82.00 → $76.00	Outperform	RBC Capital

More analyst ratings

Morphic to Present at November Investor Conferences

Chat with this insight

Recent Analyst Ratings for $MORF

$MORF Financials

Live finance-specific insights

Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

$MORF SEC Filings

SEC Form 15-12G filed by Morphic Holding Inc.

SEC Form S-8 POS filed by Morphic Holding Inc.

SEC Form S-8 POS filed by Morphic Holding Inc.

$MORF Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$MORF Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Citigroup initiated coverage on Morphic with a new price target

Stifel reiterated coverage on Morphic with a new price target

Morphic downgraded by BTIG Research

Director Edwards Martin returned 2,376 shares to the company, closing all direct ownership in the company (SEC Form 4)

Director Slattery Joseph P returned 9,066 shares to the company, closing all direct ownership in the company (SEC Form 4)

Director Nashat Amir closing all direct ownership in the company (SEC Form 4)

$MORF Press Releases

Fastest customizable press release news feed in the world

Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

Morphic to Participate in Jefferies Global Healthcare Conference

$MORF Leadership Updates

Live Leadership Updates

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

$MORF Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

$MORF Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

$MORF Market Insights

Live Market Insights

Stifel Maintains Hold on Morphic Holding, Raises Price Target to $57

Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is 'Clouded By Fed's Concerns Over Labor Market,' Analyst Warns

Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst

Recent Analyst Ratings for
$MORF

$MORF
Financials

$MORF
SEC Filings

$MORF
Analyst Ratings

$MORF
Insider Trading

$MORF
Press Releases

$MORF
Leadership Updates

$MORF
Insider Purchases

$MORF
Large Ownership Changes

$MORF
Market Insights